LetterLetter to the Editor
Response to “Clinical Relevance of CYP3A5 Genotype on Maraviroc Exposures”
Yanhui Lu, Edward J. Fuchs, Craig W. Hendrix and Namandjé N. Bumpus
Drug Metabolism and Disposition May 2015, 43 (5) 773; DOI: https://doi.org/10.1124/dmd.115.064188
Yanhui Lu
Division of Clinical Pharmacology, Departments of Medicine (Y.L., E.J.F., C.W.H., N.N.B.) and Pharmacology and Molecular Sciences (Y.L., C.W.H., N.N.B.), Johns Hopkins University School of Medicine, Baltimore, Maryland
Edward J. Fuchs
Division of Clinical Pharmacology, Departments of Medicine (Y.L., E.J.F., C.W.H., N.N.B.) and Pharmacology and Molecular Sciences (Y.L., C.W.H., N.N.B.), Johns Hopkins University School of Medicine, Baltimore, Maryland
Craig W. Hendrix
Division of Clinical Pharmacology, Departments of Medicine (Y.L., E.J.F., C.W.H., N.N.B.) and Pharmacology and Molecular Sciences (Y.L., C.W.H., N.N.B.), Johns Hopkins University School of Medicine, Baltimore, Maryland
Namandjé N. Bumpus
Division of Clinical Pharmacology, Departments of Medicine (Y.L., E.J.F., C.W.H., N.N.B.) and Pharmacology and Molecular Sciences (Y.L., C.W.H., N.N.B.), Johns Hopkins University School of Medicine, Baltimore, Maryland

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
LetterLetter to the Editor
Maraviroc and CYP3A5 Genotype
Yanhui Lu, Edward J. Fuchs, Craig W. Hendrix and Namandjé N. Bumpus
Drug Metabolism and Disposition May 1, 2015, 43 (5) 773; DOI: https://doi.org/10.1124/dmd.115.064188
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement